Foghorn Therapeutics Past Earnings Performance
Past criteria checks 0/6
Foghorn Therapeutics's earnings have been declining at an average annual rate of -11.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 66.7% per year.
Key information
-11.1%
Earnings growth rate
44.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 66.7% |
| Return on equity | n/a |
| Net Margin | -357.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41%
Jan 01
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 07Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk
Oct 22Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up
Sep 01Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking
Jul 17Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
May 09Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth
Apr 12Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too
Feb 22Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth
Dec 13Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues
Nov 07Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Jun 14Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27Revenue & Expenses Breakdown
How Foghorn Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 26 | -91 | 29 | -10 |
| 30 Jun 24 | 35 | -86 | 30 | -10 |
| 31 Mar 24 | 34 | -93 | 31 | 0 |
| 31 Dec 23 | 34 | -98 | 32 | 0 |
| 30 Sep 23 | 33 | -103 | 33 | 80 |
| 30 Jun 23 | 22 | -115 | 33 | 59 |
| 31 Mar 23 | 21 | -112 | 32 | 0 |
| 31 Dec 22 | 19 | -109 | 31 | 0 |
| 30 Sep 22 | 16 | -109 | 29 | 0 |
| 30 Jun 22 | 9 | -109 | 27 | 0 |
| 31 Mar 22 | 5 | -105 | 24 | 0 |
| 31 Dec 21 | 1 | -101 | 22 | 0 |
| 30 Sep 21 | 1 | -93 | 20 | 0 |
| 30 Jun 21 | 1 | -85 | 17 | 0 |
| 31 Mar 21 | 1 | -78 | 14 | 0 |
| 31 Dec 20 | 0 | -69 | 11 | 0 |
| 30 Sep 20 | 0 | -63 | 8 | 0 |
| 30 Jun 20 | 0 | -58 | 8 | -20 |
| 31 Mar 20 | 0 | -54 | 7 | -10 |
| 31 Dec 19 | 0 | -51 | 7 | 0 |
Quality Earnings: FHTX is currently unprofitable.
Growing Profit Margin: FHTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FHTX is unprofitable, and losses have increased over the past 5 years at a rate of 11.1% per year.
Accelerating Growth: Unable to compare FHTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FHTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: FHTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 05:55 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Foghorn Therapeutics Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | BMO Capital Markets Equity Research |
| Etzer Darout | BMO Capital Markets Equity Research |
| Gavin Clark-Gartner | Evercore ISI |